Activation of JNK and high expression level of CD133 predict a poor response to sorafenib in hepatocellular carcinoma

BACKGROUND: Hepatocellular carcinoma (HCC) ranks as the third leading cause of cancer deaths worldwide. While sorafenib, a multikinase inhibitor targeting the Raf/extracellular signal-regulated protein kinase (ERK) pathway, has been shown recently to provide a survival advantage to patients with adv...

Descripción completa

Detalles Bibliográficos
Autores principales: Hagiwara, S, Kudo, M, Nagai, T, Inoue, T, Ueshima, K, Nishida, N, Watanabe, T, Sakurai, T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Molecular Diagnostics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3388555/
https://www.ncbi.nlm.nih.gov/pubmed/22596232
http://dx.doi.org/10.1038/bjc.2012.145

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3388555/
https://www.ncbi.nlm.nih.gov/pubmed/22596232
http://dx.doi.org/10.1038/bjc.2012.145

Ejemplares similares